Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEM 2000: Optimized Strategy in Multiple Myeloma
NCT00560053Phase 3Completed
- Sponsor
- Fundación PETHEMA
- Start
- Jan 2000
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of busulfan and melphalan in multiple myeloma (MM), sponsored by Fundación PETHEMA. Primary endpoints: Toxicity and BUMEL Response Rate. Started Jan 2000; status: completed.
02
Drugs
busulfanmelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00560053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00560053.